S V Rajkumar

Summary

Affiliation: Mayo Clinic
Country: USA

Publications

  1. pmc Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1
    S Vincent Rajkumar
    Mayo Clinic, Rochester, MN, USA
    Blood 117:4691-5. 2011
  2. ncbi request reprint Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis
    S Vincent Rajkumar
    Division of Hematology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
    Clin Cancer Res 8:2210-6. 2002
  3. ncbi request reprint Current therapy for multiple myeloma
    S Vincent Rajkumar
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, Minn 55905, USA
    Mayo Clin Proc 77:813-22. 2002
  4. ncbi request reprint Thalidomide: tragic past and promising future
    S Vincent Rajkumar
    Division of Hematology, Mayo Clinic College of Medicine, Rochester, Minn 55905, USA
    Mayo Clin Proc 79:899-903. 2004
  5. ncbi request reprint Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma
    S Vincent Rajkumar
    Division of Hematology, Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    J Clin Oncol 20:4319-23. 2002
  6. ncbi request reprint Helicobacter pylori infection and monoclonal gammopathy of undetermined significance
    S Vincent Rajkumar
    Divisions of Hematology, Gastroenterology and Biostatistics, Mayo Clinic, Rochester, MN 55905, USA
    Br J Haematol 119:706-8. 2002
  7. pmc Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma
    S Vincent Rajkumar
    Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Blood 106:4050-3. 2005
  8. ncbi request reprint Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group
    S Vincent Rajkumar
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    J Clin Oncol 24:431-6. 2006
  9. ncbi request reprint Proteasome inhibition as a novel therapeutic target in human cancer
    S Vincent Rajkumar
    Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    J Clin Oncol 23:630-9. 2005
  10. ncbi request reprint Bone marrow angiogenesis and circulating plasma cells in multiple myeloma
    Shaji Kumar
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Br J Haematol 122:272-4. 2003

Collaborators

Detail Information

Publications163 found, 100 shown here

  1. pmc Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1
    S Vincent Rajkumar
    Mayo Clinic, Rochester, MN, USA
    Blood 117:4691-5. 2011
    ..We propose that future clinical trials in myeloma follow the guidelines for reporting results proposed in this manuscript...
  2. ncbi request reprint Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis
    S Vincent Rajkumar
    Division of Hematology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
    Clin Cancer Res 8:2210-6. 2002
    ..To determine whether bone marrow (BM) angiogenesis progressively increases along the spectrum of plasma cell disorders ranging from monoclonal gammopathy of undetermined significance (MGUS) to advanced myeloma...
  3. ncbi request reprint Current therapy for multiple myeloma
    S Vincent Rajkumar
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, Minn 55905, USA
    Mayo Clin Proc 77:813-22. 2002
    ..The purpose of this review is to summarize recent advances and provide an evidence-based approach to the treatment of multiple myeloma...
  4. ncbi request reprint Thalidomide: tragic past and promising future
    S Vincent Rajkumar
    Division of Hematology, Mayo Clinic College of Medicine, Rochester, Minn 55905, USA
    Mayo Clin Proc 79:899-903. 2004
  5. ncbi request reprint Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma
    S Vincent Rajkumar
    Division of Hematology, Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    J Clin Oncol 20:4319-23. 2002
    ..Thalidomide, an agent with antiangiogenic properties, is effective in relapsed myeloma. We report the results of a study combining thalidomide and dexamethasone as initial therapy for myeloma...
  6. ncbi request reprint Helicobacter pylori infection and monoclonal gammopathy of undetermined significance
    S Vincent Rajkumar
    Divisions of Hematology, Gastroenterology and Biostatistics, Mayo Clinic, Rochester, MN 55905, USA
    Br J Haematol 119:706-8. 2002
    ..pylori infection (33%) by serology, breath or stool testing between patients with MGUS and those with negative monoclonal protein studies. There was no evidence of resolution of MGUS with H. pylori therapy...
  7. pmc Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma
    S Vincent Rajkumar
    Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Blood 106:4050-3. 2005
    ..Rev/Dex is a highly active regimen with manageable side effects in the treatment of newly diagnosed myeloma...
  8. ncbi request reprint Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group
    S Vincent Rajkumar
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    J Clin Oncol 24:431-6. 2006
    ..To determine if thalidomide plus dexamethasone yields superior response rates compared with dexamethasone alone as induction therapy for newly diagnosed multiple myeloma...
  9. ncbi request reprint Proteasome inhibition as a novel therapeutic target in human cancer
    S Vincent Rajkumar
    Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    J Clin Oncol 23:630-9. 2005
    ..This article discusses proteasome inhibition as a novel therapeutic target in cancer and focuses on the development, mechanism of action, and current clinical experience with bortezomib...
  10. ncbi request reprint Bone marrow angiogenesis and circulating plasma cells in multiple myeloma
    Shaji Kumar
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Br J Haematol 122:272-4. 2003
    ..This relationship was independent of the disease activity and of the PC burden in the marrow. The increased angiogenesis may promote plasma cell proliferation and enable PC migration into the circulation...
  11. ncbi request reprint Novel therapy with 2-methoxyestradiol for the treatment of relapsed and plateau phase multiple myeloma
    S Vincent Rajkumar
    Division of Hematology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Clin Cancer Res 13:6162-7. 2007
    ..2-Methoxyestradiol (2ME2) is an endogenous product of estradiol metabolism with antiangiogenic and antineoplastic properties. We report on the first phase II trial of 2ME2 in multiple myeloma...
  12. ncbi request reprint Management of newly diagnosed myeloma
    S Vincent Rajkumar
    Division of Hematology, Department of Internal Medicine, Mayo Clinic and Foundation, College of Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Hematol Oncol Clin North Am 21:1141-56, ix-x. 2007
    ..Patients who have risk factors, such as deletion 13 or translocation t(4;14) or t(14;16), are candidates for novel, more aggressive treatments...
  13. ncbi request reprint Thalidomide in the treatment of multiple myeloma
    S V Rajkumar
    Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Expert Rev Anticancer Ther 1:20-8. 2001
    ..Major toxicities of thalidomide include constipation, sedation, skin rash, fatigue and peripheral neuropathy. This paper summarizes the current status of thalidomide in multiple myeloma...
  14. ncbi request reprint Thalidomide in multiple myeloma
    S V Rajkumar
    Mayo Medical School, Mayo Clinic and Mayo Foundation, Rochester, Minnesota, USA
    Oncology (Williston Park) 14:11-6. 2000
    ..Studies are ongoing to determine its role as initial treatment for myeloma. Trials are also underway combining thalidomide with other active agents. This article summarizes the current status of thalidomide therapy in myeloma...
  15. ncbi request reprint Prognostic value of bone marrow angiogenesis in multiple myeloma
    S V Rajkumar
    Division of Hematology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
    Clin Cancer Res 6:3111-6. 2000
    ..Angiogenesis is correlated with the plasma cell labeling index but not the bone marrow plasma cell percentage. A simple visual grading of angiogenesis is an efficient alternative to microvessel density estimation...
  16. ncbi request reprint Presence of monoclonal free light chains in the serum predicts risk of progression in monoclonal gammopathy of undetermined significance
    S Vincent Rajkumar
    Division of Hematology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Br J Haematol 127:308-10. 2004
    ..The presence of an abnormal kappa/lambda FLC ratio in the serum was associated with a higher risk of MGUS progression (relative risk 2.5; 95% confidence interval: 1.6-4.0; P < 0.001)...
  17. ncbi request reprint A review of angiogenesis and antiangiogenic therapy with thalidomide in multiple myeloma
    S V Rajkumar
    Division of Hematology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
    Cancer Treat Rev 26:351-62. 2000
    ..This paper reviews the available data on angiogenesis in myeloma, and summarizes the role of thalidomide therapy in this disease. The pharmacology and toxicity of thalidomide are also discussed...
  18. ncbi request reprint Current status of thalidomide in the treatment of cancer
    S V Rajkumar
    Division of Hematology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
    Oncology (Williston Park) 15:867-74; discussion 877-9. 2001
    ..Major toxicities associated with the use of thalidomide include constipation, sedation, skin rash, fatigue, and peripheral neuropathy. This article summarizes the current status of thalidomide therapy in cancer...
  19. ncbi request reprint Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma
    S Kumar
    Divisions of Hematology, Mayo Clinic, Rochester, MN, USA
    Leukemia 21:2035-42. 2007
    ..We recommend collection of PBSC within 6 months of initiation of therapy with lenalidomide containing regimens to minimize the risk of mobilization failures...
  20. ncbi request reprint Methods for estimation of bone marrow plasma cell involvement in myeloma: predictive value for response and survival in patients undergoing autologous stem cell transplantation
    S V Rajkumar
    Division of Hematology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Am J Hematol 68:269-75. 2001
    ..It is also prognostic for poor survival and PFS following SCT for myeloma. We recommend that all three methods of estimating BMPC% be routinely performed and that the highest value be used for prognostic purposes...
  21. ncbi request reprint Prognostic value of bone marrow angiogenesis in patients with multiple myeloma undergoing high-dose therapy
    S Kumar
    Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Bone Marrow Transplant 34:235-9. 2004
    ..007. BM MVD at the time of initial diagnosis is an important prognostic factor for OS and PFS in patients undergoing autologous transplantation as frontline therapy for myeloma...
  22. doi request reprint Impact of pretransplant therapy in patients with newly diagnosed myeloma undergoing autologous SCT
    S K Kumar
    Department of Internal Medicine, Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Bone Marrow Transplant 41:1013-9. 2008
    ..6 months for Dex and were not reached for Thal-Dex and Len-Dex groups, P=0.2. For patients undergoing early ASCT for myeloma, the nature of initial treatment utilized has no long-term impact on the outcome of ASCT...
  23. pmc Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM)
    M Q Lacy
    Division of Hematology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Leukemia 24:1934-9. 2010
    ..The combination of pomalidomide and dexamethasone (Pom/dex) is highly active and well tolerated in patients with lenalidomide-refractory myeloma...
  24. ncbi request reprint Effect of thalidomide therapy on bone marrow angiogenesis in multiple myeloma
    S Kumar
    Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA
    Leukemia 18:624-7. 2004
    ..Although not conclusive, this result lends further support to the hypothesis that angiogenesis is a relevant therapeutic target in myeloma...
  25. doi request reprint Impact of early relapse after auto-SCT for multiple myeloma
    S Kumar
    Divisions of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Bone Marrow Transplant 42:413-20. 2008
    ..Patients who relapse within 12 months of an auto-SCT have a poor outcome and should be offered trials evaluating novel treatment approaches...
  26. ncbi request reprint Thalidomide as initial therapy for early-stage myeloma
    S V Rajkumar
    Division of Hematology, Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    Leukemia 17:775-9. 2003
    ..Thalidomide has significant activity in early-stage myeloma and has the potential to delay progression to symptomatic disease. This approach must be further tested in randomized trials...
  27. ncbi request reprint High-dose therapy and autologous stem cell transplantation for multiple myeloma poorly responsive to initial therapy
    S Kumar
    Division of Hematology, Department of Medicine, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    Bone Marrow Transplant 34:161-7. 2004
    ..65). The lack of response to initial induction therapy does not appear to preclude a good response to SCT. We recommend that patients with primary refractory MM be offered early SCT...
  28. doi request reprint A phase III randomized trial of thalidomide plus zoledronic acid versus zoledronic acid alone in patients with asymptomatic multiple myeloma
    T E Witzig
    Division of Hematology, Department of Medicine, Mayo Clinic College of Medicine and Mayo Foundation, Rochester, MN, USA
    Leukemia 27:220-5. 2013
    ..The addition of Thal to standard ZLD produces anti-tumor responses whereas ZLD alone does not. Thal/ZLD also prolongs TTP from AMM to MM. This study provides the rationale for further studies in patients with AMM to delay chemotherapy...
  29. ncbi request reprint Thalidomide for previously untreated indolent or smoldering multiple myeloma
    S V Rajkumar
    Division of Hematology, Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    Leukemia 15:1274-6. 2001
    ..Additional randomized trials are needed to determine if thalidomide will delay progression to active multiple myeloma...
  30. pmc Sorafenib, a dual Raf kinase/vascular endothelial growth factor receptor inhibitor has significant anti-myeloma activity and synergizes with common anti-myeloma drugs
    V Ramakrishnan
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Oncogene 29:1190-202. 2010
    ..Sorafenib, through multiple mechanisms exerts potent anti-myeloma activity and these results favor further clinical evaluation and development of novel sorafenib combinations...
  31. ncbi request reprint Single agent dexamethasone for pre-stem cell transplant induction therapy for multiple myeloma
    S Kumar
    Division of Hematology, Department of Medicine, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    Bone Marrow Transplant 34:485-90. 2004
    ..18. No significant differences were observed in the progression-free and overall survival at 1 year post transplant. Single agent dexamethasone appears to be an effective alternative to VAD for induction therapy prior to HDT in myeloma...
  32. ncbi request reprint Eligibility for hematopoietic stem-cell transplantation for primary systemic amyloidosis is a favorable prognostic factor for survival
    A Dispenzieri
    Division of Hematology and Internal Medicine, and Section of Biostatistics, Mayo Clinic, Rochester, MN 55905, USA
    J Clin Oncol 19:3350-6. 2001
    ..This article addresses the extent to which eligibility to undergo HSCT is a favorable prognostic feature and explores prognostic factors within the subset of eligible patients...
  33. doi request reprint Melphalan and prednisone versus melphalan, prednisone and thalidomide for elderly and/or transplant ineligible patients with multiple myeloma: a meta-analysis
    P Kapoor
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Leukemia 25:689-96. 2011
    ....
  34. pmc Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: phase 1 results from the multicenter EVOLUTION study
    S K Kumar
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Leukemia 24:1350-6. 2010
    ..VDCR is well tolerated and highly active in this population. No MTD was reached; the recommended phase 2 cyclophosphamide dose in VDCR is 500 mg/m(2), which was the highest dose tested...
  35. pmc Thromboembolic events with lenalidomide-based therapy for multiple myeloma
    Smitha Patiyil Menon
    Division of Hematology, Department of Internal Medicine, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Cancer 112:1522-8. 2008
    ..The purpose was to evaluate the incidence and risk factors of thromboembolism associated with lenalidomide therapy in newly diagnosed myeloma...
  36. pmc Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients
    Francesca Gay
    Department of Internal Medicine, Division of Hematology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Blood 115:1343-50. 2010
    ..3% vs 9.2%, P = .058) and peripheral neuropathy (10.4% vs 0.9%, P < .001). Len/dex appears well-tolerated and more effective than thal/dex. Randomized trials are needed to confirm these results...
  37. pmc Disease associations with monoclonal gammopathy of undetermined significance: a population-based study of 17,398 patients
    John P Bida
    Department of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, MN 55905, USA
    Mayo Clin Proc 84:685-93. 2009
    ..To systematically study the association of monoclonal gammopathy of undetermined significance (MGUS) with all diseases in a population-based cohort of 17,398 patients, all of whom were uniformly tested for the presence or absence of MGUS...
  38. pmc High levels of peripheral blood circulating plasma cells as a specific risk factor for progression of smoldering multiple myeloma
    G Bianchi
    Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA
    Leukemia 27:680-5. 2013
    ..Overall survival (OS) after both SMM diagnosis and MM diagnosis was also significantly different. High levels of circulating PCs identify SMM patients with an elevated risk of progression within the first 2-3 years following diagnosis...
  39. ncbi request reprint ABT-737, an inhibitor of Bcl-2 family proteins, is a potent inducer of apoptosis in multiple myeloma cells
    M P Kline
    Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Leukemia 21:1549-60. 2007
    ..These data indicate that therapies targeting apoptotic pathways may be effective in MM treatment and warrant clinical evaluation of ABT-737 and similar drugs alone or in combination with other agents in the setting of MM...
  40. ncbi request reprint Translocations involving the immunoglobulin heavy-chain locus are possible early genetic events in patients with primary systemic amyloidosis
    S R Hayman
    Departments of Hematology and Internal Medicine and of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA
    Blood 98:2266-8. 2001
    ..2%) of those had translocation (11;14)(q13;q32) for an overall prevalence of the abnormality of 55%. IgH translocations are common in AL, especially the t(11;14)(q13;q32)...
  41. ncbi request reprint Combination therapy with thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma not undergoing upfront autologous stem cell transplantation: a phase II trial
    David Dingli
    Division of Hematology, Department of Internal Medicine, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Haematologica 90:1650-4. 2005
    ..We present the first data on the outcome of patients with newly diagnosed multiple myeloma treated with Thal/Dex who did not undergo upfront ASCT...
  42. ncbi request reprint Dermatologic adverse effects of lenalidomide therapy for amyloidosis and multiple myeloma
    Hans P Sviggum
    Mayo Medical School, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Arch Dermatol 142:1298-302. 2006
    ....
  43. ncbi request reprint Effect of thalidomide on stem cell collection and engraftment in patients with multiple myeloma
    I M Ghobrial
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Bone Marrow Transplant 32:587-92. 2003
    ..008), but platelet transfusion requirements did not differ (P=0.95). We concluded that thalidomide does not substantially affect peripheral cell mobilization or engraftment...
  44. pmc Relationship between elevated immunoglobulin free light chain and the presence of IgH translocations in multiple myeloma
    S Kumar
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Leukemia 24:1498-505. 2010
    ..A system including both these risk factors allows better prediction of outcome...
  45. ncbi request reprint CD45 expression by bone marrow plasma cells in multiple myeloma: clinical and biological correlations
    S Kumar
    Division of Hematology, Department of Internal Medicine, Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    Leukemia 19:1466-70. 2005
    ..07). The expression of CD138, CD56 and CD54 were higher among the CD45- PCs. This study demonstrates important biological correlates of CD45 expression on myeloma cells...
  46. ncbi request reprint Chromosome abnormalities clustering and its implications for pathogenesis and prognosis in myeloma
    C S Debes-Marun
    Mayo Clinic Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Leukemia 17:427-36. 2003
    ..Trisomy of chromosome 13 was rare ( <2%). Even among patients with abnormal karyotypes, specific chromosome abnormalities can impart biologic variability in myeloma, including several monosomies, hypodiploidy and abnormalities of 1p...
  47. ncbi request reprint A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy
    A K Stewart
    Department of Medicine, Division of Hematology Oncology, Mayo Clinic College of Medicine, Scottsdale, AZ 85259, USA
    Leukemia 21:529-34. 2007
    ..Conversely, the 75% of patients remaining have more favorable outcomes using existing - albeit non-curative - therapeutic options...
  48. ncbi request reprint Prognostic value of angiogenesis in solitary bone plasmacytoma
    Shaji Kumar
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Blood 101:1715-7. 2003
    ..02). Angiogenesis is increased in solitary plasmacytoma and is a significant predictor of progression to myeloma and provides further evidence of its importance in the pathogenesis of myeloma...
  49. pmc Suppression of uninvolved immunoglobulins defined by heavy/light chain pair suppression is a risk factor for progression of MGUS
    J A Katzmann
    Division of Clinical Biochemistry and Immunology, Department of Laboratory Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Leukemia 27:208-12. 2013
    ..8; 95% CI, 1.1-3.00; P=0.018). The finding that HLC-pair suppression predicts progression in MGUS and occurs several years before malignant transformation has implications for myeloma biology...
  50. doi request reprint MRK003, a γ-secretase inhibitor exhibits promising in vitro pre-clinical activity in multiple myeloma and non-Hodgkin's lymphoma
    V Ramakrishnan
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Leukemia 26:340-8. 2012
    ..In addition, MRK003 caused an upregulation of pAkt, indicating crosstalk with the PI3K/Akt pathway. We evaluated MRK003 in combination with Akt1/2 kinase inhibitor and observed synergy in killing MM and NHL cell lines examined...
  51. pmc Clinical value of minor responses after 4 doses of rituximab in Waldenström macroglobulinaemia: a follow-up of the Eastern Cooperative Oncology Group E3A98 trial
    Morie A Gertz
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Br J Haematol 147:677-80. 2009
    ..Future studies of Waldenström macroglobulinaemia should report minor responses because they are associated with clinically meaningful benefits. This trial was registered at http://www.clinicaltrials.gov as #NCT00005609...
  52. pmc Prognostic value of the serum free light chain ratio in newly diagnosed myeloma: proposed incorporation into the international staging system
    C L H Snozek
    Department of Laboratory Medicine and Pathology, College of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Leukemia 22:1933-7. 2008
    ..001). These findings suggest that the serum FLC ratio at initial diagnosis is an important predictor of prognosis in myeloma, and can be incorporated into the ISS for improved risk stratification...
  53. doi request reprint Improvement of cast nephropathy with plasma exchange depends on the diagnosis and on reduction of serum free light chains
    N Leung
    Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota 55905, USA
    Kidney Int 73:1282-8. 2008
    ..We found that the relationship between renal recovery and free light chain reduction was present only in patients with biopsy proven cast nephropathy showing the importance of extracorporeal light chain removal in this disease...
  54. pmc Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma
    K Detweiler Short
    Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Leukemia 25:906-8. 2011
    ..Overall survival measured from trial entry was significantly shorter for patients with treatment-emergent EMD compared with those who did not have EMD, (median 16 months versus not reached, P=0.002)...
  55. ncbi request reprint Plasma levels of tumour necrosis factor alpha and interleukin-6 predict progression-free survival following thalidomide therapy in patients with previously untreated multiple myeloma
    Michael A Thompson
    Division of Hematology, Mayo Clinic and Mayo Foundation, Rochester, MN, USA
    Br J Haematol 123:305-8. 2003
    ..01; IL-6, 24% versus 70% at 2 years, P = 0.01). None of the other parameters predicted response or PFS, and no significant changes in cytokine levels occurred with therapy...
  56. pmc Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone
    Prashant Kapoor
    Department of Internal Medicine, Division of Hematology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Blood 114:518-21. 2009
    ..These results need confirmation in larger, prospectively designed studies...
  57. ncbi request reprint Novel approaches to the management of myeloma
    S Vincent Rajkumar
    Division of Hematology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Oncology (Williston Park) 19:621-5. 2005
    ..These have shown significant clinical activity as single agents. Trials are ongoing to incorporate these new agents into the various stages of treatment and to combine them with other effective treatment modalities, including ASCT...
  58. ncbi request reprint Controversies regarding the use of dexamethasone in patients with multiple myeloma
    S Vincent Rajkumar
    Mayo Clinic, Rochester, MN, USA
    Clin Adv Hematol Oncol 6:103, 141. 2008
  59. ncbi request reprint Myeloma and the newly diagnosed patient: a focus on treatment and management
    S Vincent Rajkumar
    Mayo Medical School, 200 First Street SW, Rochester, MN 55905, USA
    Semin Oncol 29:5-10. 2002
    ..The role of supportive care strategies for patients with bone disease, such as the use of bisphosphonates, is also discussed...
  60. pmc Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma
    S V Rajkumar
    Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA
    Leukemia 27:1738-44. 2013
    ..001. There was a trend to shorter TTP with deletion 17p (median TTP, 24 months). Overall survival from diagnosis of SMM was significantly inferior with t(4;14) compared with t(11;14), median 105 versus 147 months, respectively, P=0.036. ..
  61. ncbi request reprint Thymoglobulin targets multiple plasma cell antigens and has in vitro and in vivo activity in multiple myeloma
    M M Timm
    Department of Internal Medicine, Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Leukemia 20:1863-9. 2006
    ....
  62. ncbi request reprint A phase I study of 153Sm-EDTMP with fixed high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma
    A Dispenzieri
    Department of Internal Medicine, Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Leukemia 19:118-25. 2005
    ..Overall response rate was 94% including seven very good partial responses and five complete responses. Addition of 153Sm EDTMP to melphalan conditioning appears to be safe, well-tolerated and worthy of further study...
  63. doi request reprint Clarithromycin (Biaxin)-lenalidomide-low-dose dexamethasone (BiRd) versus lenalidomide-low-dose dexamethasone (Rd) for newly diagnosed myeloma
    Francesca Gay
    Division of Hematology, Department of Internal Medicine, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Am J Hematol 85:664-9. 2010
    ..5% vs. 4.2%, P = 0.129) were higher with Rd. Results of this case-matched analysis suggest that there is significant additive value when clarithromycin is added to Rd. Randomized phase III trials are needed to confirm these results...
  64. pmc Evidence for cytogenetic and fluorescence in situ hybridization risk stratification of newly diagnosed multiple myeloma in the era of novel therapie
    Prashant Kapoor
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Mayo Clin Proc 85:532-7. 2010
    ..This study validates the high-risk features defined by FISH and CG in the Mayo risk-stratification model for patients with MM predominantly treated with novel therapies based on immunomodulatory agents...
  65. ncbi request reprint Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myeloma
    Shaji Kumar
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, Minn 55905, USA
    Mayo Clin Proc 78:34-9. 2003
    ..To assess response rate, duration of response, progression-free survival, and toxicity of thalidomide in patients with relapsed multiple myeloma...
  66. ncbi request reprint Thalidomide in newly diagnosed multiple myeloma and overview of experience in smoldering/indolent disease
    S Vincent Rajkumar
    Division of Hematology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Semin Hematol 40:17-22. 2003
    ..Phase III trials of thalidomide in newly diagnosed symptomatic multiple myeloma or smoldering/indolent disease are ongoing...
  67. pmc Circulating plasma cells detected by flow cytometry as a predictor of survival in 302 patients with newly diagnosed multiple myeloma
    Grzegorz S Nowakowski
    Division of Hematology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Blood 106:2276-9. 2005
    ..We conclude that the number of circulating PCs measured by flow cytometry in patients with newly diagnosed MM is an independent predictor of survival...
  68. ncbi request reprint Effect of allogeneic stem cell transplantation on bone marrow angiogenesis in chronic myelogenous leukemia
    S Kumar
    Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Bone Marrow Transplant 32:1065-9. 2003
    ..However, there was no significant change in MVD following transplant (P=0.8, paired t-test). Abnormal bone marrow angiogenesis appears to persist in the bone marrow following ASCT for CML, at least in the short term...
  69. ncbi request reprint Therapeutic application of thalidomide in multiple myeloma
    R A Kyle
    Division of Hematology, Department of Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Semin Oncol 28:583-7. 2001
    ..Prior chemotherapy had failed and five (16%) patients had experienced relapse following stem cell transplantation. Ten (38%) of the 26 patients who had received at least two cycles of therapy obtained a response...
  70. ncbi request reprint Angiogenesis in multiple myeloma
    S V Rajkumar
    Division of Hematology, Mayo Clinic and Mayo Foundation, 200 First Street SW, Rochester, MN 55905, USA
    Semin Oncol 28:560-4. 2001
    ..The finding of increased angiogenesis in myeloma provides the rationale for the study of antiangiogenic therapy in this disease...
  71. pmc Flow cytometric detection of circulating myeloma cells before transplantation in patients with multiple myeloma: a simple risk stratification system
    David Dingli
    Division of Hematology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Blood 107:3384-8. 2006
    ..4, and 6.5 months, respectively. CMCs at the time of ASCT is an independent prognostic factor and in combination with cytogenetics provides a powerful scoring system that stratifies patients and guides management...
  72. pmc The importance of bone marrow examination in determining complete response to therapy in patients with multiple myeloma
    Cheng E Chee
    Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Blood 114:2617-8. 2009
    ..2 years vs 2.3 years, respectively; P = .01)...
  73. ncbi request reprint Bone marrow angiogenesis in multiple myeloma: effect of therapy
    Shaji Kumar
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Br J Haematol 119:665-71. 2002
    ..We conclude that the degree of bone marrow angiogenesis is a prognostic marker in patients with multiple myeloma and does not decrease significantly after therapy...
  74. ncbi request reprint Fracture risk in monoclonal gammopathy of undetermined significance
    L Joseph Melton
    Division of Epidemiology, Department of Health Sciences Research, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
    J Bone Miner Res 19:25-30. 2004
    ..There was a 2.7-fold increase in the risk of axial fractures but no increase in limb fractures. The pathophysiologic basis for the increased axial fractures should be determined...
  75. ncbi request reprint Prognostic value of circulating plasma cells in monoclonal gammopathy of undetermined significance
    Shaji Kumar
    Department of Internal Medicine, Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    J Clin Oncol 23:5668-74. 2005
    ..Identification of patients with MGUS at high risk of progression will allow development of preventive strategies. We studied the prognostic value of circulating plasma cells (PCs) in patients with MGUS to predict progression...
  76. ncbi request reprint Biological and prognostic significance of interphase fluorescence in situ hybridization detection of chromosome 13 abnormalities (delta13) in multiple myeloma: an eastern cooperative oncology group study
    Rafael Fonseca
    Department of Hematology and Internal Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer Res 62:715-20. 2002
    ..03). The presence of Delta13 is an important and independent adverse prognostic factor in newly diagnosed MM and is associated with specific biological features...
  77. pmc Clinical features and treatment response of light chain (AL) amyloidosis diagnosed in patients with previous diagnosis of multiple myeloma
    Sumit Madan
    Division of Hematology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Mayo Clin Proc 85:232-8. 2010
    ..To identify and assess the clinical features and treatment response of light chain (AL) amyloidosis diagnosed in patients with previous diagnosis of multiple myeloma (MM)...
  78. doi request reprint Genetic aberrations and survival in plasma cell leukemia
    R E Tiedemann
    Division of Hematology and Oncology, Mayo Clinic, Scottsdale, AZ, USA
    Leukemia 22:1044-52. 2008
    ..Poor survival in pPCL was predicted by MYC translocation (P=0.006). Survival in sPCL was consistently short. Overall pPCL and sPCL are different disorders with distinct natural histories, genetics and survival...
  79. pmc Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma
    J T Larsen
    Division of Hospital Internal Medicine, Department of Medicine, Mayo Clinic, Rochester, MN, USA
    Leukemia 27:941-6. 2013
    ..We conclude that a high FLC ratio 100 is a predictor of imminent progression in SMM, and such patients may be considered candidates for early treatment intervention...
  80. doi request reprint Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study
    S K Kumar
    Divison of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Leukemia 26:149-57. 2012
    ..This study confirms the poor outcome, once patients become refractory to current treatments. The results provide context for interpreting ongoing trials of new drugs...
  81. doi request reprint Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management
    R A Kyle
    Division of Hematology, Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Leukemia 24:1121-7. 2010
    ..Testing should be done 2-3 months after the initial recognition of SMM. If the results are stable, the patient should be followed every 4-6 months for 1 year and, if stable, every 6-12 months...
  82. ncbi request reprint Thalidomide as an anti-cancer agent
    S Kumar
    Division of Hematology, Department of Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    J Cell Mol Med 6:160-74. 2002
    ..We have concisely reviewed the current knowledge regarding mechanisms of its anti-neoplastic activity and the results of various clinical trials in oncology...
  83. ncbi request reprint Waldenström's macroglobulinemia
    M A Gertz
    Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Oncologist 5:63-7. 2000
    ..The median survival of symptomatic patients is 65 months. Patients without symptoms should not be treated...
  84. pmc Impact of vitamin D deficiency on the clinical presentation and prognosis of patients with newly diagnosed multiple myeloma
    Alvin C Ng
    Division of Endocrinology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA
    Am J Hematol 84:397-400. 2009
    ..Am. J. Hematol. 2009. (c) 2009 Wiley-Liss, Inc...
  85. ncbi request reprint Acquired Fanconi syndrome is an indolent disorder in the absence of overt multiple myeloma
    Cynthia X Ma
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Blood 104:40-2. 2004
    ..In conclusion, FS associated with monoclonal gammopathy does not appear to confer an additional risk of subsequent evolution to MM. ESRD occurs late in the disease process...
  86. pmc Clinical implication of centrosome amplification in plasma cell neoplasm
    Wee J Chng
    Division of Hematology Oncology, Mayo Clinic, Johnson Research Bldg, 13400 E Shea Blvd, Scottsdale, AZ, USA
    Blood 107:3669-75. 2006
    ....
  87. ncbi request reprint Bone marrow angiogenic ability and expression of angiogenic cytokines in myeloma: evidence favoring loss of marrow angiogenesis inhibitory activity with disease progression
    Shaji Kumar
    Division of Hematology and Internal Medicine, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Blood 104:1159-65. 2004
    ..The active inhibition of angiogenesis in MGUS is lost with progression, and the angiogenic switch from MGUS to NMM may involve a loss of inhibitory activity...
  88. ncbi request reprint Thalidomid: current role in the treatment of non-plasma cell malignancies
    Shaji Kumar
    Department of Internal Medicine, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    J Clin Oncol 22:2477-88. 2004
    ..This article reviews the current status of thalidomide for the treatment of non-plasma-cell malignancies...
  89. ncbi request reprint Fracture risk with multiple myeloma: a population-based study
    L Joseph Melton
    Division of Epidemiology, Department of Health Sciences Research, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    J Bone Miner Res 20:487-93. 2005
    ..Pathologic fractures, especially of the axial skeleton, are extremely common in patients with multiple myeloma and cluster around the time of diagnosis. Osteoporotic fractures seem to be less of a problem in these patients...
  90. ncbi request reprint Expression of VEGF and its receptors by myeloma cells
    S Kumar
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Leukemia 17:2025-31. 2003
    ..Demonstration of the presence of VEGFR2 in our study provides a potential biological explanation for the preclinical activity observed with VEGFR2 inhibitors...
  91. pmc Risk of acute leukemia and myelodysplastic syndromes in patients with monoclonal gammopathy of undetermined significance (MGUS): a population-based study of 17 315 patients
    L E Roeker
    Mayo Medical School, Mayo Clinic, Rochester, MN, USA
    Leukemia 27:1391-3. 2013
    ..4 (95% CI 1.08, 5.32), P=0.031. There was no statistically significant increase in the risk of AML (RR 1.36 P=0.675), and no increased risk of developing ALL...
  92. ncbi request reprint Long-term follow-up of IgM monoclonal gammopathy of undetermined significance
    R A Kyle
    Division of Hematology and Internal Medicine, Section of Biostatistics, Mayo Clinic, Rochester, MN 55905, USA
    Semin Oncol 30:169-71. 2003
    ..The risk of progression of MGUS of IgM type to lymphoma or related disorders averaged 1.5% per year throughout the period of observation...
  93. pmc Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma
    R A Kyle
    Department of Internal Medicine, Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Leukemia 23:3-9. 2009
    ..This paper provides the current criteria for diagnosis, staging, risk stratification and response assessment of MM...
  94. ncbi request reprint Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma
    R Fonseca
    Division of Hematology and Oncology, Mayo Clinic Comprehensive Cancer Center, Scottsdale, AZ 85259, USA
    Leukemia 20:2034-40. 2006
    ..Both 1q21 gain and increase gene expression level were significantly associated with reduced survival. However, neither is an independent prognostic marker in MM on multivariate Cox proportional hazard analysis...
  95. pmc Serum immunoglobulin free light chain measurements and heavy chain isotype usage provide insight into disease biology in patients with POEMS syndrome
    Trista Stankowski-Drengler
    Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA
    Am J Hematol 85:431-4. 2010
    ..In summary, serum immunoglobulin profiles are unique in POEMS syndrome as compared with other plasma cell disorders...
  96. doi request reprint Treatment of myeloma: cure vs control
    S Vincent Rajkumar
    Division of Hematology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Mayo Clin Proc 83:1142-5. 2008
  97. pmc Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study
    Angela Dispenzieri
    Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Lancet 375:1721-8. 2010
    ..The remaining 20% are characterised by absence of IgH expression; we aimed to assess prevalence of a corresponding precursor entity, light-chain MGUS...
  98. pmc Increased risk of monoclonal gammopathy in first-degree relatives of patients with multiple myeloma or monoclonal gammopathy of undetermined significance
    Celine M Vachon
    Division of Epidemiology, Department of Health Sciences Research, College of Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Blood 114:785-90. 2009
    ..0; 95% CI, 1.4 to 2.8) and MGUS probands (RR, 3.3; 95% CI, 2.1 to 4.8). The increased risk of MGUS in first-degree relatives of MGUS or MM patients implies shared environment and/or genetics...
  99. pmc Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1{beta}-induced interleukin 6 production and the myeloma proliferative component
    John A Lust
    Division of Hematology, Mayo Clinic, Rochester, MN 55905
    Mayo Clin Proc 84:114-22. 2009
    ..To conduct in vitro studies as well as a phase 2 clinical trial in patients with smoldering or indolent multiple myeloma to determine if interleukin 1 (IL-1) inhibitors can delay or prevent active myeloma...
  100. ncbi request reprint Review of 1027 patients with newly diagnosed multiple myeloma
    Robert A Kyle
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, Minn 55905, USA
    Mayo Clin Proc 78:21-33. 2003
    ..To determine the clinical and laboratory features of newly diagnosed multiple myeloma...
  101. pmc Prevention of progression in monoclonal gammopathy of undetermined significance
    S Vincent Rajkumar
    Division of Hematology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Clin Cancer Res 15:5606-8. 2009
    ..Because myeloma is an incurable malignancy, strategies to delay or prevent progression in high-risk patients are of considerable importance...